BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 21563231)

  • 1. Loss of heterozygosity proximal to the M6P/IGF2R locus is predictive for the presence of disseminated tumor cells in the bone marrow of ovarian cancer patients before and after chemotherapy.
    Kuhlmann JD; Schwarzenbach H; Otterbach F; Heubner M; Wimberger P; Worm KH; Kimmig R; Kasimir-Bauer S
    Genes Chromosomes Cancer; 2011 Aug; 50(8):598-605. PubMed ID: 21563231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival.
    Kuhlmann JD; Schwarzenbach H; Wimberger P; Poetsch M; Kimmig R; Kasimir-Bauer S
    BMC Cancer; 2012 Jul; 12():325. PubMed ID: 22849543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer.
    Schwarzenbach H; Pantel K; Kemper B; Beeger C; Otterbach F; Kimmig R; Kasimir-Bauer S
    Breast Cancer Res; 2009; 11(5):R71. PubMed ID: 19772563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A critical evaluation of loss of heterozygosity detected in tumor tissues, blood serum and bone marrow plasma from patients with breast cancer.
    Schwarzenbach H; Müller V; Beeger C; Gottberg M; Stahmann N; Pantel K
    Breast Cancer Res; 2007; 9(5):R66. PubMed ID: 17915011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer.
    Wimberger P; Heubner M; Otterbach F; Fehm T; Kimmig R; Kasimir-Bauer S
    Gynecol Oncol; 2007 Nov; 107(2):331-8. PubMed ID: 17764727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression.
    Schwarzenbach H; Eichelser C; Kropidlowski J; Janni W; Rack B; Pantel K
    Clin Cancer Res; 2012 Oct; 18(20):5719-30. PubMed ID: 23014523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of loss of heterozygosity of the tumor suppressor genes p53 and BRCA1 in ovarial carcinomas].
    Petrović B; Perović M; Novaković I; Atanacković J; Popović B; Luković L; Petković S
    Vojnosanit Pregl; 2006 Sep; 63(9):813-8. PubMed ID: 17039893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer.
    Schwarzenbach H; Chun FK; Lange I; Carpenter S; Gottberg M; Erbersdobler A; Friedrich MG; Huland H; Pantel K
    Int J Cancer; 2007 Apr; 120(7):1465-71. PubMed ID: 17205532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of disseminated tumor cells in patients with gynecological cancers.
    Fehm T; Becker S; Bachmann C; Beck V; Gebauer G; Banys M; Wallwiener D; Solomayer EF
    Gynecol Oncol; 2006 Dec; 103(3):942-7. PubMed ID: 16889820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Loss of heterozygosity at chromosome 3p14, 25 in serum DNA from ovarian cancer patients].
    Zhang H; Li Z; Chen M; Zhang G; Xu K
    Zhonghua Fu Chan Ke Za Zhi; 2002 May; 37(5):298-300. PubMed ID: 12133406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53.
    Werness BA; Parvatiyar P; Ramus SJ; Whittemore AS; Garlinghouse-Jones K; Oakley-Girvan I; DiCioccio RA; Wiest J; Tsukada Y; Ponder BA; Piver MS
    J Natl Cancer Inst; 2000 Jul; 92(13):1088-91. PubMed ID: 10880552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor (M6P/IGF2R) locus predisposes patients to radiation-induced lung injury.
    Kong FM; Anscher MS; Sporn TA; Washington MK; Clough R; Barcellos-Hoff MH; Jirtle RL
    Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):35-41. PubMed ID: 11163495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of tumor-specific genetic alterations in bone marrow from early-stage breast cancer patients.
    Taback B; Giuliano AE; Hansen NM; Singer FR; Shu S; Hoon DS
    Cancer Res; 2003 Apr; 63(8):1884-7. PubMed ID: 12702578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Explorative investigation of vascular endothelial growth factor receptor expression in primary ovarian cancer and its clinical relevance.
    Wimberger P; Chebouti I; Kasimir-Bauer S; Lachmann R; Kuhlisch E; Kimmig R; Süleyman E; Kuhlmann JD
    Gynecol Oncol; 2014 Jun; 133(3):467-72. PubMed ID: 24713547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High throughput detection of M6P/IGF2R intronic hypermethylation and LOH in ovarian cancer.
    Huang Z; Wen Y; Shandilya R; Marks JR; Berchuck A; Murphy SK
    Nucleic Acids Res; 2006; 34(2):555-63. PubMed ID: 16432260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.
    Wang C; Horiuchi A; Imai T; Ohira S; Itoh K; Nikaido T; Katsuyama Y; Konishi I
    J Pathol; 2004 Feb; 202(2):215-23. PubMed ID: 14743504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible involvement of loss of heterozygosity in malignant transformation of ovarian endometriosis.
    Xu B; Hamada S; Kusuki I; Itoh R; Kitawaki J
    Gynecol Oncol; 2011 Feb; 120(2):239-46. PubMed ID: 21130491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy.
    Aktas B; Kasimir-Bauer S; Heubner M; Kimmig R; Wimberger P
    Int J Gynecol Cancer; 2011 Jul; 21(5):822-30. PubMed ID: 21613958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: from the Danish "MALOVA" Ovarian Carcinoma Study.
    Høgdall EV; Ryan A; Kjaer SK; Blaakaer J; Christensen L; Bock JE; Glud E; Jacobs IJ; Høgdall CK
    Cancer; 2004 Jun; 100(11):2387-95. PubMed ID: 15160342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microsatellite alterations plasma DNA of primary breast cancer patients.
    Shaw JA; Smith BM; Walsh T; Johnson S; Primrose L; Slade MJ; Walker RA; Coombes RC
    Clin Cancer Res; 2000 Mar; 6(3):1119-24. PubMed ID: 10741742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.